Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Acadia Pharmaceuticals (ACAD)

Acadia Q3 revenue rises 11% to $278.6 million; raises NUPLAZID sales guidance

Positive Impact 4 of 5 earnings Written later

Acadia Pharmaceuticals reported third quarter 2025 total revenue of $278.6 million, up 11% from a year earlier, and net income of $71.8 million, or $0.42 per diluted share, compared with $32.8 million a year earlier. The company raised its 2025 NUPLAZID net product sales guidance and lowered the top of its DAYBUE sales range while narrowing it; the net income gain includes a one-time tax benefit.

Key points

  • Q3 2025 total revenue of $278.6 million, up 11% year-over-year; NUPLAZID sales $177.5 million and DAYBUE sales $101.1 million
  • Q3 net income of $71.8 million ($0.42 diluted) vs. $32.8 million ($0.20) in Q3 2024, including a one-time tax benefit tied to the One Big Beautiful Bill Act
  • 2025 total revenue guidance of $1.070 to $1.095 billion, vs. prior $1.045 to $1.095 billion; NUPLAZID guidance raised to $685 to $695 million from $665 to $690 million
  • Cash, cash equivalents and investment securities of $847.0 million at September 30, 2025

The filing

CompanyAcadia Pharmaceuticals (ACAD)
Form8-K, current report
Filed with the SECNov 5, 2025, 4:13 PM ET
Accession number0001193125-25-266959

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:38 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.